Claims for Patent: 9,636,407
✉ Email this page to a colleague
Summary for Patent: 9,636,407
Title: | Caspofungin acetate formulations |
Abstract: | A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture. |
Inventor(s): | Jiang; John Zhiqiang (Chicago, IL), Usayapant; Arunya (Mundelein, IL), Bowman; David (Mattawan, MI), Kwok; Keith (Long Grove, IL), Peterson; Joel (New Lenox, IL) |
Assignee: | FRESENIUS KABI USA, LLC (Lake Zurich, IL) |
Application Number: | 13/724,266 |
Patent Claims: |
1. A composition, comprising: from 10 to 150 mg of caspofungin acetate, and arginine, where the mass ratio of the arginine to caspofungin acetate is from 1:1 to 3:1; where
the composition is a solid.
2. The composition of claim 1, comprising from 25 to 100 mg caspofungin acetate. 3. The composition of claim 1, comprising from 50 to 70 mg caspofungin acetate. 4. The composition of claim 1, where the mass ratio of the arginine to caspofungin acetate is 2:1. 5. A composition, comprising: 50 mg caspofungin acetate, and arginine; where the mass ratio of arginine to caspofungin acetate is from 1:1 to 3:1, and the composition is a solid. 6. The composition of claim 5, where the mass ratio of arginine to caspofungin acetate is 2:1. 7. A composition, formed by a method comprising: forming a liquid mixture comprising a solvent, from 10 to 150 mg of caspofungin acetate, and arginine, where the mass ratio of arginine to caspofungin acetate is from 1:1 to 3:1; and lyophilizing the liquid mixture to form a solid composition. 8. The composition of claim 7, comprising from 25 to 100 mg caspofungin acetate. 9. The composition of claim 7, comprising from 50 to 70 mg caspofungin acetate. 10. The composition of claim 7, where the mass ratio of arginine to caspofungin acetate is 2:1. 11. The composition of claim 1, wherein following storage of the composition at 25.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 1.0% as determined by peak area percent using High Pressure Liquid Chromatography. 12. The composition of claim 1, wherein following storage of the composition at 40.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 2.0% as determined by peak area percent using High Pressure Liquid Chromatography. 13. The composition of claim 5, wherein following storage of the composition at 25.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 1.0% as determined by peak area percent using High Pressure Liquid Chromatography. 14. The composition of claim 5, wherein following storage of the composition at 40.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 2.0% as determined by peak area percent using High Pressure Liquid Chromatography. 15. The composition of claim 6, wherein following storage of the composition at 25.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 1.0% as determined by peak area percent using High Pressure Liquid Chromatography. 16. The composition of claim 6, wherein following storage of the composition at 40.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 2.0% as determined by peak area percent using High Pressure Liquid Chromatography. 17. A composition, comprising: 70 mg caspofungin acetate, and arginine; where the mass ratio of arginine to caspofungin acetate is from 1:1 to 3:1, and the composition is a solid. 18. The composition of claim 17, where the mass ratio of arginine to caspofungin acetate is 2:1. 19. The composition of claim 17, wherein following storage of the composition at 25.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 1.0% as determined by peak area percent using High Pressure Liquid Chromatography. 20. The composition of claim 17, wherein following storage of the composition at 40.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 2.0% as determined by peak area percent using High Pressure Liquid Chromatography. 21. The composition of claim 18, wherein following storage of the composition at 25.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 1.0% as determined by peak area percent using High Pressure Liquid Chromatography. 22. The composition of claim 18, wherein following storage of the composition at 40.degree. C. for a period of 29 days, the amount of total impurities present in the composition is not more than 2.0% as determined by peak area percent using High Pressure Liquid Chromatography. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.